<DOC>
	<DOCNO>NCT00004011</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know surgery plus combination chemotherapy effective surgery alone non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness surgery without combination chemotherapy treat patient non-small cell lung cancer .</brief_summary>
	<brief_title>S9900 : Surgery With Without Combination Chemotherapy Treating Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival patient previously untreated stage IB , II , select IIIA non-small cell lung cancer preoperative chemotherapy comprise paclitaxel carboplatin plus surgery v surgery alone . - Compare regimens term operative mortality toxic effect patient . - Evaluate response rate ( confirm unconfirmed ) toxic effect associate combined paclitaxel carboplatin patient . - Obtain sample correlation radiologic , pathologic , molecular , biologic factor outcome patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord clinical stage ( IB IIA v IIB IIIA ) . Patients randomize one two treatment arm : - Arm I : Patients undergo thoracotomy . All accessible hilar ( level 10 ) lymph node dissect , complete mediastinal lymph node sample perform . - Arm II : Patients receive paclitaxel IV 3 hour follow carboplatin IV 30 minute day 1 . Treatment repeat every 3 week maximum 3 course absence disease progression unacceptable toxicity . Within 2-6 week course 3 , patient undergo thoracotomy lymph node dissection arm I . Patients follow every 3 month 1 year , every 6 month 5 year , annually year 10 . PROJECTED ACCRUAL : A total 600 patient ( 300 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven nonsmall cell lung cancer ( NSCLC ) , meet 1 follow stag criterion : Stage IB ( T2 , N0 ) Stage II T12 , N1 negative mediastinoscopy OR T3 , N0 Selected stage IIIA negative mediastinoscopies T3 , N1 , exclude superior sulcus Positive level 10 hilar node allow mediastinoscopy negative Apical tumor clinical symptom allow No symptomatic tumor ( T3 , N0 T3 , N1 ) involve superior sulcus No Pancoast 's tumor Negative mediastinoscopy require patient clinically positive mediastinal hilar lymph node ensure N2 disease Bidimensionally measurable evaluable disease chest xray contrastenhanced CT scan T3 , N0 disease assessable bronchoscopy must affirm 2 observer document photograph include main carina PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 0 1 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 WBC least 4,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN Alkaline phosphatase great 2 time ULN Renal : Creatinine great 1.5 time ULN Creatinine clearance least 50 mL/min Pulmonary : See Disease Characteristics Preresection FEV_1 great 2.0 L OR Predicted postresection FEV_1 great 1.0 L No postobstructive pneumonia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious infection No serious medical condition would preclude study compliance No prior allergic reaction drug contain Cremophor No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy NSCLC No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior systemic radiotherapy NSCLC No concurrent radiotherapy Surgery : At least 5 year since prior resection lung disease Other : No concurrent investigational therapy No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
</DOC>